Crémieux: Viagra for Life Extension Does It Work? I'm Doubtful

Key Takeaways

• MR studies show no dementia protection, possible risk increase
• Observational data suggest 70% lower Alzheimer risk, but unconfirmed
• Regular PDE5 use raises ocular adverse events up to 2.6‑fold
• Clinicians should balance uncertain cognitive benefits against eye safety

Pulse Analysis

The allure of repurposing well‑known drugs for longevity has turned phosphodiesterase‑5 (PDE5) inhibitors into a hot topic among biotech investors and health‑conscious consumers. Viagra and Cialis, originally approved for erectile dysfunction and pulmonary hypertension, have been touted for cardiovascular benefits that could translate into longer, healthier lives. This narrative fuels a burgeoning market for “longevity supplements,” prompting pharmaceutical firms to explore off‑label uses and investors to fund early‑stage trials that promise high returns if a clear neuroprotective signal emerges.

Genetic Mendelian‑randomisation (MR) studies provide a quasi‑experimental lens on drug effects by using inherited variants that mimic pharmacologic inhibition. Two 2025 MR analyses examined PDE5 inhibition and dementia risk. One found a modest increase in Alzheimer’s (OR 1.09) and Lewy‑body dementia (OR 1.32), while the other reported no causal link to Alzheimer’s. These results suggest that, at a population‑genetic level, PDE5 inhibition is unlikely to confer neuroprotection and may even raise risk for certain dementias. The divergence between the two studies underscores the complexity of translating genetic proxies into clinical outcomes, especially when effect sizes are small and confidence intervals narrow.

Observational cohorts paint a more optimistic picture, with one large study noting a 70 % lower Alzheimer incidence among regular Viagra users. Yet such associations can be confounded by healthier lifestyles, better access to care, or selection bias. Meanwhile, safety data reveal a 1.85‑fold increase in ocular adverse events, including a 2.58‑times rise in serous retinal detachment. For clinicians, the prudent approach is to weigh the uncertain cognitive upside against tangible eye‑risk, reserving PDE5 inhibitors for approved indications and discussing any off‑label longevity aspirations transparently with patients. As the scientific community seeks definitive trials, the current evidence base advises caution rather than enthusiasm.